Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma

Lymphomas encompass a group of malignancies that originate in the lymph nodes or other lymphoid tissues. Epigenetic modification, especially by histone deacetylase (HDACs), plays a key role during the occurrence and development of lymphomas. Consequently, HDAC inhibitors (HDACIs), a class of gene ex...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & medicine Vol. 9; no. 2; pp. 85 - 89
Main Authors Guo, Shan-Qi, Zhang, Yi-Zhuo
Format Journal Article
LanguageEnglish
Published China Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China 01.06.2012
Chinese Anti-Cancer Association
China Anti-Cancer Association
Subjects
epigenomics
histone deacetylases
lymphoma
Review
therapeutics
epigenomics
histone deacetylases
therapeutics
lymphoma
Online AccessGet full text

Cover

More Information
Summary:Lymphomas encompass a group of malignancies that originate in the lymph nodes or other lymphoid tissues. Epigenetic modification, especially by histone deacetylase (HDACs), plays a key role during the occurrence and development of lymphomas. Consequently, HDAC inhibitors (HDACIs), a class of gene expression-modulating drugs, have emerged as promising mechanism-based agents for the treatment of lymphomas. This review presents the rationale of HDAC inhibition, describes the epigenetic-based mechanisms of action of HDACIs, discusses their clinical efficiency, and summarizes the current and future developments in this field.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Yi-zhuo Zhang
E-mail: aprilzyz@yahoo.com
ISSN:2095-3941
2095-3941
DOI:10.3969/j.issn.2095-3941.2012.02.001